FDA found Roque Plast hand sanitizer labeled 70% ethanol contained 25% methanol and was refused import.
What happened
FDA tested a batch of COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER that was detained at the U.S. border after an import attempt. The product was labeled as made at Roque Plast's Mexico facility and to contain 70% ethanol, but FDA found an average of 38% ethanol and 25% methanol. FDA also cited unapproved-new-drug and misbranding violations; the firm recalled the product nationwide on August 4, 2020.
What FDA found
The hand sanitizer's active ingredient ethanol was substituted in part with methanol, a toxic chemical not acceptable for hand sanitizers.
FD&C Act section 501(d)(2), 21 U.S.C. 351(d)(2)The methanol substitution showed that quality assurance at the facility was not working under Current Good Manufacturing Practice (CGMP) requirements.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The product was marketed as a new drug without FDA approval and did not meet the conditions for marketing without approval.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a), 331(d); section 505GThe label said 70% ethanol, but testing found less ethanol and undeclared methanol, making the labeling false and misleading.
FD&C Act section 502(a), 21 U.S.C. 352(a)The label failed to list methanol as an ingredient.
FD&C Act section 502(e)(1)(A), 21 U.S.C. 352(e)(1)(A)The product was dangerous to health when used as labeled because of methanol.
FD&C Act section 502(j), 21 U.S.C. 352(j)
What FDA wants
FDA asks Roque Plast to investigate how ethanol was replaced with methanol, list raw materials and suppliers, provide batch records and reconciliation, and commit to testing every ethanol lot for methanol using the USP method in an FDA-inspected CGMP lab. The firm must respond in writing within 15 working days.
Who should pay attention
- brands selling or distributing hand sanitizers
- companies buying sanitizer from Mexican contract manufacturers
- retailers and importers of consumer antiseptics
This is a summary. Read the original letter on fda.gov.